National Coalition for Cancer Survivorship (NCCS) State of Cancer Survivorship: Survey Results

 The National Coalition for Cancer Survivorship (NCCS) has released the results of a survey conducted on more than 2100 cancer patients, survivors, and caregivers between August and September 2024. Findings from the survey, presented in report format, discuss treatment decision-making, post-treatment care, participation in clinical trials, side effects of treatment, and financial hardship.  

Click here to view the survey briefing video and download the survey results. 

Short-course of induction chemotherapy followed by chemoradiotherapy significantly improves survival in patients with locally advanced cervical cancer

 Results of INTERLACE, a phase III multicentre randomized study is the first to "show a significant survival advantage with the addition of induction chemotherapy before chemoradiotherapy in locally advanced cervical cancer."  5-year progression-free survival was significant: 72% in patients administered induction chemotherapy with chemoradiotherapy, compared to 64% receiving chemoradiotherapy alone. 

To learn more about this study, click here. 

Sources mentioned: 

• McCormack M, Eminowicz G, Gallardo D, et al. on behalf of the INTERLACE investigators. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. The Lancet 2024;404(10462):P1525-1525.
• 
  
• Duska LR, Randall LM. Progress in the treatment paradigms for locally advanced cervical cancer. The Lancet 2024;404(10462):p1494-1496.